Get vaccinated now with mRNA or later with dead vaccine?
Why the wait is not worth it
Created: 01/07/2022, 1:38 PM
From: Juliane Gutmann
Many struggle with the new mRNA vaccination technology.
But is waiting for the dead vaccines the solution?
There are some arguments against it.
For a long time, only vector and mRNA vaccines were available as part of the corona vaccination campaign. On December 20, 2021, the European Medicines Agency (EMA) recommended the approval of Novavax's inactivated vaccine. After approval by the EU Commission, it will be the fifth vaccine to be approved in the EU. However, according to the Robert Koch Institute (RKI), the products from Astrazenca and Johnson & Johnson (both vector vaccines *) and the vaccines from Moderna and Biontech / Pfizer (mRNA vaccines) that have been vaccinated so far can be equated with dead vaccines. The reason for this, according to the RKI: They do not contain any viruses that can replicate.
Inactivated vaccines would contain killed pathogens or pathogen components that neither multiply nor cause disease. This applies to both the mRNA and the vector vaccines, it said
Another reason that speaks against waiting for the dead vaccines: The two most promising dead vaccine candidates are not yet available. The Novavax preparation Nuvaxovid was approved by the EMA. However, it may take some time before the vaccine is available in Germany. “Germany has contractually secured a vaccine from Novavax, which can also be vaccinated in Germany once it has been approved by the EU.
We are currently waiting for the company to announce the specific delivery dates
, ”quoted the newspaper
a spokesman for the Federal Ministry of Health.
The EU Commission had already signed a purchase agreement with Novavax for up to 100 million vaccine doses at the beginning of August.
Germany has so far requested 16 million doses of Novavax.
The vaccine from the Franco-Austrian pharmaceutical company Valneva is also considered a beacon of hope in the field of dead vaccines.
It is currently being examined by the European Medicines Agency.
On December 20, 2021, the European Medicines Agency (EMA) recommended the approval of the first protein-based corona vaccine Nuvaxovid from the pharmaceutical company Novavax.
: Pumped full of medicine on the ward: This is how Covid patients are kept alive - doctor appeals "Get the vaccination"
Long-term observations are lacking in the case of dead corona vaccines
It is therefore uncertain in what quantities the dead vaccines will actually be available and from when exactly.
But time is of the essence: the faster a large part of the population is vaccinated, the better.
Because the corona vaccination protects against severe Covid-19 and against life-threatening courses of illness
, as health authorities inform.
Bayerischer Rundfunk also points out that there is no reason to assume that these vaccines could be safer, more reliable or in any other way better than the vaccines that are currently used in Germany.
In addition, it is unclear how long the vaccination protection lasts and when a booster vaccination is necessary.
Another shortcoming: Inactivated vaccines have not been inoculated billions of times like mRNA and vector vaccines.
Accordingly, there is a lack of detailed information on very rare side effects
that did not occur in the approval studies.
(jg) * Merkur.de is an offer from IPPEN.MEDIA.